Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Teleflex IncorporatedNYSE: TFX

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit declines year over year

Q2 FY2026 gross profit of $331.71M fell 23.1% year over year, behind the -17.3% change in trailing-twelve-month gross profit. Sequentially, it rose 7.9% from the prior quarter. Over 3 fiscal years it compounded at -9.9% a year.

Context

  • Gross profit amounted to 56.2% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -23.1% toward the trailing-twelve-month pace of -17.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$331.71M+7.9% QoQ
Last fiscal yearDec 2025
$1.12B-34.2% YoY
LTMJun 2026
$1.4B-17.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.1%——
1 year-34.2%——
3-year CAGR-9.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
1.12B USD
Year-over-year change
-34.2%
4-year CAGR
-7.8%

Gross Profit vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.3% is the 9th highest of 11, against a peer median of +11.0%.
  • Gross profit amounts to 53.8% of revenue for TFX, versus a peer median of 82.7%.
TFX Competitors
Gross Profit for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$3.04B USD+9.3%+7.5%57.2%
ALKSAlkermes plcLTM Sep 2026$1.45B USD+11.0%+12.7%82.9%
TFXTeleflex IncorporatedLTM Jun 2026$1.4B USD-17.3%-9.9%53.8%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$828.57M USD-51.6%+36.4%82.1%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$796.04M USD+11.3%+12.4%49.4%
TGTXTG Therapeutics, Inc.LTM Sep 2026$742.84M USD+63.7%+489.2%82.7%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$449.02M USD-45.9%+25.3%99.6%
KRYSKrystal Biotech, Inc.LTM Jun 2026$411.14M USD+22.6%—93.3%
STVNStevanato Group S.p.A.LTM Jun 2026€356.38M EUR+11.0%+1.1%29.2%
PCVXVaxcyte, Inc.LTM Jun 2026-$865K USD+82.7%——
CRSPCRISPR Therapeutics AGLTM Sep 2026-$140.69M USD-4.7%—558.9%
Peer median (excluding TFX) —+11.0%+12.7%82.7%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.81B2.79B2.97B3.05B1.99B
Cost of Revenue1.26B1.26B1.33B1.34B871.96M
Gross Profit1.55B1.53B1.65B1.7B1.12B
Gross Margin55.2%54.9%55.4%55.9%56.2%
Research & Development130.84M153.82M154.35M161.67M144.78M
Selling, General & Admin860.09M863.75M929.87M995.27M720.17M
Operating Expenses921.51M1.03B1.14B1.55B864.95M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
EBITDA853.8M730.77M761.21M433.62M302.51M
EBITDA Margin30.4%26.2%25.6%14.2%15.2%
Operating Income628.1M499.73M506.31M151.01M255.8M
Operating Margin22.4%17.9%17.0%5.0%12.8%
Interest Income1.33M912K12.78M8.01M6.4M
Interest Expense56.97M54.26M85.08M83.54M100.22M
Other Income / Expenses(68.63M)(53.81M)(72.3M)(75.54M)(231.25M)
Income Before Tax559.47M445.92M434.01M75.48M24.55M
Pre-Tax Margin19.9%16.0%14.6%2.5%1.2%
Income Tax Expense74.35M83M76.44M5.32M(33.98M)
Net Income485.37M363.14M356.33M69.68M(905.64M)
Net Margin17.3%13.0%12.0%2.3%-45.4%
EPS (Basic)10.387.747.581.49(20.30)
EPS (Diluted)10.237.687.531.48(20.25)
Weighted Avg Shares46.77M46.9M46.98M46.84M44.62M
Weighted Avg Shares (Diluted)47.43M47.31M47.3M47.09M44.72M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.